Crossmark

Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice

Crossref DOI link: https://doi.org/10.1186/s13195-019-0498-8

Published Online: 2019-05-10

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

de Retana, Sofía Fernández

Marazuela, Paula

Solé, Montse

Colell, Guillem

Bonaterra, Anna

Sánchez-Quesada, Jose Luis

Montaner, Joan

Maspoch, Daniel

Cano-Sarabia, Mary

Hernández-Guillamon, Mar
Funding

Funding for this research was provided by:

Instituto de Salud Carlos III (PI17/00275, PI17/00275, PI13/00364, RD16/0019/0021)

Fundació la Marató de TV3 (40/U/2014)
License Information

Text and Data Mining valid from 2019-05-10
More Information

Article History

Received: 19 December 2018

Accepted: 23 April 2019

First Online: 10 May 2019

Ethics approval

: Animal use for this study was approved by the Ethics Committee for Animal Experimentation of Vall d’Hebron Research Institute (CEEA 78/13) and conducted in compliance with Spanish legislation and the Directives of the European Union.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.